Answers are grounded in this paper and cite their sources.
., CML diagnosed at age < 3 years, children presenting with specific problems at diagnosis or during course of treatment) which had not been described before. Publications coming from the IR-PCML disseminated this useful information derived from patients who robustly participate and share information about their disease, among themselves and with their caregivers and clinicians. Patient input driving the collection of data on this rare leukemia is the basis for the considerable success of bringing new therapeutics into clinical use.
No takes yet. Share an insight, caveat, or question.
Suttorp et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: